Skip to main content

CombiMatrix Revenues Up in Q2, Losses Down

NEW YORK, July 23 (GenomeWeb News) - CombiMatrix Thursday reported $750,000 in revenues for the second quarter, up from $6,000 in the same quarter of last year.

 

Revenues were down significantly compared to the first quarter, when the company recorded $17.6 million in revenues, $17.3 million of which were deferred revenues under a 15-year microarray development contract with Roche the companies signed in 2001.

https://www.genomeweb.com/articles/view-article.asp?Article=200173142836

 

The company, a Mulkiteo, Wash., subsidiary of Acacia Research, recorded a net loss of $3.5 million, compared to $5.2 million in the same period of 2003.

 

R&D expenses were $2.1 million, compared to $2.2 million in the same period of 2003.

 

As of June 30, CombiMatrix had $28.9 million in cash, cash equivalents and short-term investments, compared to $17.3 million at the end of 2003. In April, Acacia Research raised $13.7 million in a stock sale of Acacia Research - CombiMatrix common stock, and attributed the proceeds to CombiMatrix.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.